[Market Focus] Daiwa Pharmaceutical Proves No Difference in Survival Between Oral Paclitaxel and Injectable Form, Shares Rise

Daiwa Pharmaceutical is showing strong performance. This is believed to be due to the news that oral paclitaxel (DHP107) demonstrated non-inferiority compared to intravenous (IV) paclitaxel in a Phase 3 clinical trial.

As of 9:26 a.m. on June 2, Daiwa Pharmaceutical was trading at 17,020 won, up 3.84% from the previous day.

According to industry sources, Daiwa Pharmaceutical announced at the American Society of Clinical Oncology 2025 (ASCO), held in Chicago, United States, on May 31, that oral paclitaxel (DHP107) demonstrated non-inferiority compared to IV paclitaxel in a Phase 3 clinical trial.

The progression-free survival (PFS) and overall survival (OS) of each group were similar, while the DHP107 group showed a higher objective response rate (ORR). However, neutropenia occurred more frequently in the DHP107 group. The research team analyzed that DHP107 overall exhibited a manageable toxicity profile.

DHP107 had previously been approved as a gastric cancer treatment in Korea and China.

The clinical trial targeted patients with HER2-negative recurrent or metastatic breast cancer (mBC). The study evaluated whether DHP107 was non-inferior to IV paclitaxel, and enrolled patients who had received at least one prior hormone-based therapy but had not undergone chemotherapy for metastatic breast cancer.

The results showed that the median progression-free survival (mPFS) was 10.02 months in the DHP107 group and 8.54 months in the IV paclitaxel group, demonstrating the non-inferiority of DHP107.

This content was produced with the assistance of AI translation services.